Cue Biopharma: Shao-Lee Lin proposes $305K share sale

Lin's reported prior sales were 40,000 shares on August 12 and 18,258 shares on August 13, 2026.

Rhea-AI Filing Summary

Shao-Lee Lin, identified as an officer and director of Cue Biopharma, Inc., proposes to sell 11,087 common shares on October 12, 2026, at an aggregate market value of $305,490.35. Lin says the proposed sale will cover tax withholding obligations tied to restricted stock unit vesting and settlement and is not discretionary.

Key Figures

Proposed common shares: 11,087 shares Aggregate market value: $305,490.35 Common shares sold: 40,000 shares +3 more

6 metrics

Proposed common shares 11,087 shares Proposed sale on October 12, 2026

Aggregate market value $305,490.35 Proposed sale

Common shares sold 40,000 shares August 12, 2026

Gross proceeds $1,080,400 Sale on August 12, 2026

Common shares sold 18,258 shares August 13, 2026

Gross proceeds $515,971 Sale on August 13, 2026

Key Terms

Restricted Stock Units, sell to cover, tax withholding obligations

3 terms

Restricted Stock Units financial

"Restricted Stock Units vesting under registered plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover technical

"funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

tax withholding obligations financial

"cover tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Cue Biopharma (CUE) shares does Shao-Lee Lin propose to sell?

Shao-Lee Lin proposes to sell 11,087 common shares on October 12, 2026, at an aggregate market value of $305,490.35.

What prior sales did Shao-Lee Lin report for Cue Biopharma (CUE)?

Shao-Lee Lin reported selling 40,000 common shares on August 12, 2026, for gross proceeds of $1,080,400, and 18,258 common shares on August 13, 2026, for gross proceeds of $515,971.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 08:57 PM EDT Accepted by SEC EDGAR 10/13/2026 - 08:56 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001725092
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CUE BIOPHARMA, INC.
SEC File Number	001-38327
Address of Issuer	100 CHESTNUT STREET SUITE 300 SOMERVILLE MASSACHUSETTS 02143
Phone	617-949-2680
Name of Person for Whose Account the Securities are To Be Sold	Shao-Lee Lin
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Maxim Group LLC 300 Park Ave 16th Floor New York NY 10022	11087	305490.35	7809832	10/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/09/2026	Restricted Stock Units vesting under registered plan	Issuer			11087	10/09/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Shao-Lee Lin 100 Chestnut Street, Suite 300 c/o Cue Biopharma, Inc. Somerville MA 02143	Common Stock	08/12/2026	40000	1080400
Shao-Lee Lin 100 Chestnut Street, Suite 300 c/o Cue Biopharma, Inc. Somerville MA 02143	Common Stock	08/13/2026	18258	515971

144: Remarks and Signature

Remarks	The proposed sales reported represent shares to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The purpose of the proposed sales is to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the reporting person.
Date of Notice	10/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Shao-Lee Lin
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)